<p><em>欧洲专利局（EPO）已授予 Ada Health 一项专利，涉及其混合人工智能架构——一种结合大型语言模型优势的集成方法，具备临床精确性、可解释性和合规性。</em></p>
<p>, /PRNewswire/ -- Ada Health 是一家领先的临床人工智能公司，帮助人们理解症状并安全高效地导航医疗，今天宣布 EPO 已授予 Ada 的混合临床人工智能架构专利。该专利认可了 Ada 的集成方法的新颖性：一个将大型语言模型与其专有的概率图模型相结合的系统，提供比单独使用任何一种方法更准确、更用户友好的解决方案。</p>
<p>人工智能现在已成为大规模健康问题的主要入口。但通用大型语言模型的临床安全性弱点越来越受到关注：独立研究已识别出紧急情况的低级别分类、错误和幻觉。Ada 的系统提供了现代语言模型的对话灵活性与医疗所需的临床严谨性，而不是在两者之间做出选择。</p>
<p><em>&#34;大型语言模型提供商正在发现规模与医疗安全并不相同。Ada 花费了十多年时间构建使人工智能在医疗中安全部署的临床基础设施——经过验证的知识库、监管认证和安全协议。该专利保护了将所有这些与现代语言模型的力量结合在一起的架构。这是行业一直在等待的临床层。&#34;</em></p>
<p><strong>— Daniel Nathrath，Ada Health 创始人兼首席执行官</strong></p>
<p><strong>专利保护的内容</strong></p>
<p>Ada 的混合引擎在前端包含一个大型语言模型，允许用户用自己的话描述症状、病史、药物和偏好，捕捉到对复杂或罕见病症的预诊断至关重要的临床细微差别和上下文细节。该系统动态提示用户与医疗相关的后续问题，限制在 Ada 的经过验证的知识库内，防止因在临床环境中不受限制使用大型语言模型而产生的无根据输出。这是内置于架构中的结构性保障。最后，专利混合模型独立评估症状，LLM 作为 Ada 的专家策划医疗知识库的第二意见。两个模型是集成的：Ada 的推理引擎充当护栏，同时提高相对准确性超过 7%，并保持医疗级部署所需的严谨性。</p>
<p>最终结果是一个完全透明、可审计的临床推理系统。自 2016 年以来，Ada 的输出数据洞察和可解释性在大规模人群中运行，继续成为其全球领先的制药、健康系统和支付方合作伙伴的重要特征。</p>
<p><em>&#34;工程挑战不在于构建一个混合体，而在于构建一个临床严谨性与对话灵活性相互增强而非相互妥协的混合体。Ada 的架构通过设计解决了这一点：大型语言模型捕捉用户想要表达的内容，Ada 的概率模型和集成解决方案确定其临床意义，而 Ada 的推理引擎始终是决策者。这使得它在受监管的环境中安全、可解释且可部署。&#34;</em></p>
<p><strong>— Graham French，Ada Health 首席技术官</strong></p>
<p>在 EPO 授予专利后，Ada 将把其混合方法扩展到其制药、健康系统和支付方合作伙伴中，安全性和可解释性是前提条件。</p>
<p><strong>关于专利</strong></p>
<p>涵盖 Ada Health 混合架构的专利（EP4679451B1）已由欧洲专利局正式授予，并于 2026 年 3 月 25 日生效，优先日期为 2024 年 7 月 12 日。</p>
<p><strong>关于 Ada Health</strong></p>
<p>Ada Health 结合临床专业知识和先进的人工智能，帮助个人和健康组织更早地采取行动。由医生、科学家和工程师构建，Ada 应用概率推理技术于一个医疗专家策划的知识库，将现实世界数据转化为可操作的指导，赋能个人理解其症状，并帮助医疗和生命科学领域的合作伙伴提供更及时、个性化的护理。作为欧盟医疗器械法规（MDR）下的 IIa 类医疗器械，Ada 的评估已进行超过 5000 万次，并有 50 多篇独立的同行评审出版物，受到全球领先健康系统、保险公司和制药公司的信任。了解更多信息，请访问 about.ada.com。</p>
<p>Logo - https://mma.prnewswire.com/media/2953902/Ada_Health_Logo.jpg</p>
<p>来源：Ada Health</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEzJk5ld3NJdGVtSWQ9TE4zMTYzOCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTMwODI0UFJfTkVXU19VU1BSX19fX19MTjMxNjM4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEzJk5ld3NJdGVtSWQ9TE4zMTYzOCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTMwODI0UFJfTkVXU19VU1BSX19fX19MTjMxNjM4"/></p>

PRTC

阿卡迪亚医疗保健

AHCO

PRTCY

<p>Ada Health 已获得欧洲专利局授予的专利，专利内容为其混合人工智能架构，该架构将大型语言模型（LLMs）与临床精确性和合规性相结合。该创新系统通过将概率图模型与 LLM 集成，提高了医疗保健的准确性和用户友好性。该专利架构通过动态提示用户相关的医学问题，并通过 Ada 的专家策划知识库提供第二意见，从而确保临床安全。此项发展旨在改善人工智能在医疗保健中的应用，解决与通用 LLM 相关的安全问题</p>

<p><em>The European Patent Office (EPO) has granted Ada Health a patent for its hybrid AI architecture — an ensembling approach that combines the strengths of large language models with clinical precision, explainability, and regulatory standing.</em></p>
<div class="lb-trans"><p><em>欧洲专利局（EPO）已授予 Ada Health 一项专利，涉及其混合人工智能架构——一种结合大型语言模型优势的集成方法，具备临床精确性、可解释性和合规性。</em></p>
</div><p>, /PRNewswire/ -- Ada Health, a leading clinical AI company that helps people understand their symptoms and navigate care safely and efficiently, today announced that the EPO has granted a patent for Ada's hybrid clinical AI architecture. The patent recognizes the novelty of Ada's ensembling approach: a system that combines an LLM with its proprietary probabilistic graphical model to deliver a solution that is more accurate and user-friendly than either approach alone.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Ada Health 是一家领先的临床人工智能公司，帮助人们理解症状并安全高效地导航医疗，今天宣布 EPO 已授予 Ada 的混合临床人工智能架构专利。该专利认可了 Ada 的集成方法的新颖性：一个将大型语言模型与其专有的概率图模型相结合的系统，提供比单独使用任何一种方法更准确、更用户友好的解决方案。</p>
</div><p>AI is now a primary entry point for health questions at scale. But the clinical safety weaknesses of general-purpose LLMs are increasingly well-documented: independent research has identified under-triage of emergencies, errors, and hallucinations. Rather than choosing between the conversational flexibility of modern language models and the clinical rigour that healthcare demands, Ada's system delivers both.</p>
<div class="lb-trans"><p>人工智能现在已成为大规模健康问题的主要入口。但通用大型语言模型的临床安全性弱点越来越受到关注：独立研究已识别出紧急情况的低级别分类、错误和幻觉。Ada 的系统提供了现代语言模型的对话灵活性与医疗所需的临床严谨性，而不是在两者之间做出选择。</p>
</div><p><em>&#34;LLM providers are discovering that scale and medical safety are not the same. Ada has spent over a decade building the clinical infrastructure that makes AI safe to deploy in healthcare — the validated knowledge base, the regulatory certification, the safeguarding protocols. This patent protects the architecture that brings all of that together with the power of modern language models. It is the clinical layer the industry has been waiting for.&#34;</em></p>
<div class="lb-trans"><p><em>&#34;大型语言模型提供商正在发现规模与医疗安全并不相同。Ada 花费了十多年时间构建使人工智能在医疗中安全部署的临床基础设施——经过验证的知识库、监管认证和安全协议。该专利保护了将所有这些与现代语言模型的力量结合在一起的架构。这是行业一直在等待的临床层。&#34;</em></p>
</div><p><strong>— Daniel Nathrath, Founder and CEO, Ada Health</strong></p>
<div class="lb-trans"><p><strong>— Daniel Nathrath，Ada Health 创始人兼首席执行官</strong></p>
</div><p><strong>What the Patent Protects</strong></p>
<div class="lb-trans"><p><strong>专利保护的内容</strong></p>
</div><p>Ada's hybrid engine includes an LLM on the front end, which allows users to describe symptoms, medical history, medications, and preferences in their own words, capturing the clinical nuance and contextual detail crucial to pre-diagnosing complex or rare conditions. The system dynamically prompts users with medically relevant follow-up questions constrained to Ada's validated knowledge base, preventing ungrounded outputs that arise from unconstrained LLM use in clinical settings. This is a structural safeguard built into the architecture. Finally, the patented hybrid model assesses symptoms independently, with the LLM functioning as a second opinion alongside Ada's expert-curated medical knowledge base. The two models are ensembled: Ada's reasoning engine acts as a guardrail, while improving relative accuracy by more than 7% and preserving the rigour that medical-grade deployments demand.</p>
<div class="lb-trans"><p>Ada 的混合引擎在前端包含一个大型语言模型，允许用户用自己的话描述症状、病史、药物和偏好，捕捉到对复杂或罕见病症的预诊断至关重要的临床细微差别和上下文细节。该系统动态提示用户与医疗相关的后续问题，限制在 Ada 的经过验证的知识库内，防止因在临床环境中不受限制使用大型语言模型而产生的无根据输出。这是内置于架构中的结构性保障。最后，专利混合模型独立评估症状，LLM 作为 Ada 的专家策划医疗知识库的第二意见。两个模型是集成的：Ada 的推理引擎充当护栏，同时提高相对准确性超过 7%，并保持医疗级部署所需的严谨性。</p>
</div><p>The result is a fully white-box, auditable clinical reasoning system. The data insight and explainability of Ada's outputs, which have been running at population scale since 2016, continues to be a crucial feature for its industry-leading pharma, health systems, and payer partners around the world.</p>
<div class="lb-trans"><p>最终结果是一个完全透明、可审计的临床推理系统。自 2016 年以来，Ada 的输出数据洞察和可解释性在大规模人群中运行，继续成为其全球领先的制药、健康系统和支付方合作伙伴的重要特征。</p>
</div><p><em>&#34;The engineering challenge is not building a hybrid, it's making one where clinical rigour and conversational flexibility reinforce each other rather than trade off. Ada's architecture resolves that by design: the LLM captures what users want to say, Ada's probabilistic model and ensemble solution determine what it means clinically, and Ada's reasoning engine is always the decision-maker. That is what makes it safe, explainable, and deployable in regulated environments.&#34;</em></p>
<div class="lb-trans"><p><em>&#34;工程挑战不在于构建一个混合体，而在于构建一个临床严谨性与对话灵活性相互增强而非相互妥协的混合体。Ada 的架构通过设计解决了这一点：大型语言模型捕捉用户想要表达的内容，Ada 的概率模型和集成解决方案确定其临床意义，而 Ada 的推理引擎始终是决策者。这使得它在受监管的环境中安全、可解释且可部署。&#34;</em></p>
</div><p><strong>— Graham French, Chief Technology Officer, Ada Health</strong></p>
<div class="lb-trans"><p><strong>— Graham French，Ada Health 首席技术官</strong></p>
</div><p>Following the EPO patent grant, Ada will extend its hybrid approach across its pharma, health systems, and payers partners, where safety and explainability are prerequisites.</p>
<div class="lb-trans"><p>在 EPO 授予专利后，Ada 将把其混合方法扩展到其制药、健康系统和支付方合作伙伴中，安全性和可解释性是前提条件。</p>
</div><p><strong>About the Patent</strong></p>
<div class="lb-trans"><p><strong>关于专利</strong></p>
</div><p>The patent (EP4679451B1) covering Ada Health's hybrid architecture was officially granted by the European Patent Office and went into effect on March 25, 2026, with a priority date of July 12, 2024.</p>
<div class="lb-trans"><p>涵盖 Ada Health 混合架构的专利（EP4679451B1）已由欧洲专利局正式授予，并于 2026 年 3 月 25 日生效，优先日期为 2024 年 7 月 12 日。</p>
</div><p><strong>About Ada Health</strong></p>
<div class="lb-trans"><p><strong>关于 Ada Health</strong></p>
</div><p>Ada Health combines clinical expertise and advanced AI to help people and health organizations act on insights earlier. Built by doctors, scientists, and engineers, Ada applies probabilistic reasoning technology to a medical expert-curated knowledge base that transforms real-world data into actionable guidance, empowering individuals to understand their symptoms and helping partners across healthcare and life sciences deliver more timely, personalized care. As a Class IIa medical device under the EU's Medical Device Regulation (MDR), with over 50 million assessments and 50+ independent peer-reviewed publications, Ada's assessment is trusted by leading health systems, insurers, and pharmaceutical companies around the world. Learn more at about.ada.com.</p>
<div class="lb-trans"><p>Ada Health 结合临床专业知识和先进的人工智能，帮助个人和健康组织更早地采取行动。由医生、科学家和工程师构建，Ada 应用概率推理技术于一个医疗专家策划的知识库，将现实世界数据转化为可操作的指导，赋能个人理解其症状，并帮助医疗和生命科学领域的合作伙伴提供更及时、个性化的护理。作为欧盟医疗器械法规（MDR）下的 IIa 类医疗器械，Ada 的评估已进行超过 5000 万次，并有 50 多篇独立的同行评审出版物，受到全球领先健康系统、保险公司和制药公司的信任。了解更多信息，请访问 about.ada.com。</p>
</div><p>Logo - https://mma.prnewswire.com/media/2953902/Ada_Health_Logo.jpg</p>
<div class="lb-trans"><p>Logo - https://mma.prnewswire.com/media/2953902/Ada_Health_Logo.jpg</p>
</div><p>SOURCE Ada Health</p>
<div class="lb-trans"><p>来源：Ada Health</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEzJk5ld3NJdGVtSWQ9TE4zMTYzOCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTMwODI0UFJfTkVXU19VU1BSX19fX19MTjMxNjM4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN31638&amp;Transmission_Id=202604130824PR_NEWS_USPR_____LN31638&amp;DateId=20260413"/></p>

Ada Health 为确保大型语言模型在医疗保健中安全的临床层申请了专利